The size of the Middle East and Africa Intrauterine devices (IUD’S) Market was worth USD 273.61 million in 2022 and estimated to reach USD 344.40 million by the end of 2027, with a growing potential of 4.71% from 2022 to 2027.
The intrauterine device (IUD) is most used for reversible family planning method across the world. The earlier IUDs made up of inert plastic materials have largely been archaic in modern practice by products which release levonorgestrel or copper, modifications which significantly enhance high efficacy. The intrauterine contraceptive device is a safe, effective and convenient contraceptive method. The use of IUDs has been limited in less developed countries due to increase in menstrual blood loss which has been a significant issue. So, the most population has been preferred to use the levonorgestrel releasing IUD (LNg IUD) which is highly effective, long-lasting and reduces the blood loss during menstruation in less developed countries.
Technical innovations, increasing prevalence of STD’S (Sexually transmitted diseases), direct health benefits other than birth control, increasing government initiatives to prevent unwanted abortions and pregnancies are driving the growth of the market in Middle East and Africa. The factors that are hampering the growth of the market are issues of Infertility, Side effects, ectopic pregnancy, pelvic inflammatory infection, and Limited access to contraception.
This research report segmented and sub-segmented the Middle East and Africa Intrauterine Devices Market into the following categories:
By End User:
Companies leading the MEA Intrauterine Devices Market are Agile Therapeutics, Actavis PLC, ANI Pharmaceuticals Inc., Bayer, Teva Pharmaceutical, Besins HealthCare, Brecuro Medical, Effik International, Eurogine, HLL Lifecare, HRA Pharma, Lupin Pharmaceuticals, Ltd, Okamato Industries, Inc. and Pfizer.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: email@example.com